MRI-guided focused ultrasound is providing patients with essential tremor a non-invasive, lesion-free alternative to traditional surgical procedures [1, 2].
This medical advancement matters because it allows patients to reduce tremor symptoms quickly without the recovery downtime or risks associated with invasive brain surgery. By targeting specific areas of the brain using ultrasound waves, the procedure offers a viable option for those who cannot undergo traditional surgery or seek minimal side effects [1, 2].
Clinical data released in September 2023 demonstrates that the treatment maintains efficacy for at least five years without progressive or delayed complications [2]. The technology, developed by medical-device company Insightec, has seen increasing adoption across several U.S. medical centers, including Johns Hopkins Hospital in Baltimore [1, 2].
Access to the treatment has expanded through insurance and regional rollout. Humana announced a positive coverage decision for the procedure in September 2023 [3]. In Florida, the treatment became available in Miami on April 22, 2025 [4]. Additionally, Orange Park Hospital has been utilizing focused ultrasound to treat patients for more than two years as of April 2026 [5].
Recent milestones indicate a growing patient volume for the technology. UHS reported treating its 100th patient with focused ultrasound for essential tremor in January 2026 [6]. Neurosurgeon William Anderson and neurologist Emile Moukheiber of Johns Hopkins Medicine said the procedure improves quality of life for those suffering from debilitating tremors [1].
The procedure relies on MRI guidance to ensure precision, allowing clinicians to monitor the treatment in real time. This ensures that the ultrasound energy is focused exactly where it is needed to curb the tremor without damaging surrounding healthy tissue [1, 2].
“MRI-guided focused ultrasound is providing patients with essential tremor a non-invasive, lesion-free alternative to traditional surgical procedures.”
The shift toward non-invasive neuromodulation represents a significant transition in treating movement disorders. By securing both long-term efficacy data and insurance coverage from major providers like Humana, the treatment is moving from a niche clinical innovation to a standard care option. This reduces the barrier to entry for patients who previously avoided treatment due to the risks of invasive surgery.
